Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
The Financial Express14m
Lilly’s Zepbound outshines Wegovy in weight loss head-to-head trial
Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green ...
Ibj.com1h
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...
Why do people on Ozempic and other obesity drugs lose interest in alcohol
Weight loss medications like Ozempic, Wegovy, and Mounjaro are not only effective in curbing appetite but also in reducing ...
The Root on MSN16h
5 Inconvenient Truths About Ozempic, Wegovy and Other Semaglutides, According to Doctors
On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...
E!16h
Khloe Kardashian Shares How She Really Feels About the Ozempic Trend
Khloe Kardashian shared what she really thinks of Ozempic, the Type 2 diabetes drug commonly used for weight management.
JD Supra20h
GLP-1 Drugs: Brand Companies Push FDA to Limit Compounding
Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...
What's on Netflix18h
Netflix News
Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...